FILE:MON/MON-8K-20020801085907.txt.gz
EVENTS:	Financial statements and exhibits	
TEXT:
ITEM: Financial statements and exhibits
ITEM: 
ITEM 7.      FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c)     
Exhibits
ITEM 9.      REGULATION FD DISCLOSURE
         The attached presentation will be used, in whole or in part and possibly with modifications, by our Chief Executive Officer or other senior executives, including our Chief Financial Officer, Chief Operating Officer and Chief Technology Officer, in connection with presentations to investors, securities analysts and other members of the financial and investment community at various times from about August 1, 2002, to about August 13, 2002.
         We are furnishing the information contained in Exhibit 99.1 pursuant to Regulation FD promulgated by the Securities and Exchange Commission ("SEC"). This information is furnished pursuant to Item 9 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. By filing this Item 9 of Form 8-K and furnishing the information in Exhibit 99.1, we make no admission as to the materiality of such information that is required to be disclosed solely by reason of Regulation FD or that the information includes material investor information that is not otherwise publicly available.
         The information contained in this Item 9 and in Exhibit 99.1 is information that is intended to be considered in the context of our SEC filings and other public announcements that we may make, by press release or otherwise, from time to time. We disclaim any current intention to revise or update the information contained in this Item 9 or in Exhibit 99.1, although we may do so from time to time as our management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
         A copy of the attached presentation is available for viewing under the "Investors" page on our website located at , although we reserve the right to discontinue that availability at any time.
http:\\www.monsanto.com
         Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:   August 1, 2002

EXHIBIT 99.1
Spinoff of Monsanto from Pharmacia August 2002
Forward-Looking Statements
Certain statements contained in this presentation, such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, currency impact, business and financial plans and other non-historical facts are "forward-looking statements." These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: fluctuations in exchange rates and other developments related to foreign currencies and economies; increased generic and branded competition for the company's Roundup herbicide; the success of the company's research and development activities and the speed with which regulatory authorizations and product launches may be achieved; domestic and foreign social, legal and political developments, especially those relating to agricultural products developed through biotechnology; the accuracy of the company's estimates and projections, for example, those with respect to product returns and grower use of our products and related distribution inventory levels; the company's ability to continue to manage its costs; the company's ability to successfully market new and existing products in new and existing domestic and international markets; the company's ability to obtain payment for the products that it sells; the company's ability to achieve and maintain protection for its intellectual property; the effects of the company's accounting policies and changes in generally accepted accounting principles; the company's exposure to lawsuits and other liabilities and contingencies, including those related to intellectual property, product liability, regulatory compliance (including seed quality), environmental contamination and antitrust; the effect of weather conditions and commodity markets on the agriculture business; the company's ability to fund its short-term financing needs; general economic and business conditions; any changes in business, political and economic conditions due to threat of future terrorist activity and related military action; and other risks and factors detailed in the company's filings with the U.S. Securities and Exchange Commission. The company disclaims any current intention to revise or update any forward-looking statements or any of the factors that may affect actual results, whether as a result of new information, future events or otherwise.
Transaction Overview
Record Date:          July 29
Distribution date:          August 13
Total # of shares to be distributed:        220 million
Distribution ratio:          0.17
Investment Highlights
Deliver Near-Term Growth and Preserve Long-Term Value
Strong core businesses
Growing biotechnology business with great upside
Leadership position in genomics and seeds
Broadest and deepest pipeline in the industry
Steady profit and cash growth through innovation and cost management
Overview of Monsanto
Roundup herbicide - No. 1 in market share
Other selective herbicides
Animal agriculture
Lawn-and-garden business
$4.9 billion
Sales
Twelve months June 30, 2002
Ag Productivity - 68% Seeds and Genomics - 32%
Leading global position in seeds and biotech traits
"Best in Class" genomics platforms
Monsanto Is Investing in Growth Segment of Agriculture
Industry Gross Profit Pool
Biotech/Seed
2000 - 2004F $1.8 B Gross Profit Gain
Ag Chem
2000 - 2004F $1.6 B Gross Profit Loss
2001 R&D Investment
Monsanto
Ag Chem - 17% Biotech & Seeds - 83%
Rest of Industry Average
Ag Chem - 71% Biotech & Seeds - 29%
Source: Phillips McDougall, Monsanto estimates
Since the IPO, We've Delivered On ...
Effective management of Roundup post-patent
Roundup brand maintained 55% market share worldwide; 80% U.S.
Glyphosate molecule share of 80% worldwide; 90% U.S.
Integration and upgrade of the seed business
Integration of seed acquisitions completed early
U.S. share of corn and soybeans both up 2 share points
Portfolio upgrade continues with 75% of portfolio less than 3 years old
Strong grower adoption of biotech traits
Monsanto global biotech trait acreage up 37% from 90 million acres in 1999 to 123 million acres in 2001
"Best in class" R&D
More than 15 new Roundup formulations worldwide
More than 150 new seed hybrids/varieties worldwide
Advanced key biotech registrations; two new product launches in 2003
Strong cost management
SG&A down $54M and R&D down $135M from 1999 to 2001
Positive free cash flow
Free cash flow turned positive in 2001 at $183 million; projected at $400 million - $460 million in 2002
But Challenges Remain; Going Forward We're Committed to ...
Managing Roundup successfully in a post-patent environment
Continuing to build on strong seed performance
Growing current biotech traits in existing markets
Delivering pipeline and winning approvals in new markets and for new traits
Mitigating risk in Latin American operations
Delivering earnings and free cash flow growth
Seed and Traits Will Drive Gross Profit
Gross profit ($ millions)
Roundup Brand Is Unique in Ag Industry
2000 sales ($millions)
All Other Glyphosate - 823 Imidacloprid - 544 Azoxystrobin - 450 Paraquat - 427 Acetochlor - 360 Chlorpyrifos - 345 Metalachlor - 285 2,4-D - 280 Fipronil - 270 Mancozeb - 250 Atrazine - 240
Roundup - 2,422*
Source: Phillips McDougall, 2001 * Branded and 3rd party supply revenue
Roundup Strategy Differentiates Brand
Integrated Solutions with Seed and Biotech
Create incremental value for grower and retailer
Capture brand premium from integrated solutions
Build Customer/Distribution Relationships
Maintain top customer ratings
Capitalize on logistics capabilities
Maintain Molecule and Brand Leadership
Capture molecule share through supply agreements
Offer differentiated products
Grow Capacity while Reducing Cost
Maintain low-cost position
Build Large Market and Grow Volume
Capture price elasticity gains
Grow con-till acres
Expand Roundup Ready crops
Roundup Outside U.S. Grows with Market
Roundup Brand
Millions of gallons
Glyphosate Molecule*
Millions of gallons
* Roundup brand plus 3rd party supply
U.S. Roundup Sales to Match Product Use
Roundup Brand
Millions of gallons
Glyphosate Molecule*
Millions of gallons
* Roundup brand plus 3rd party supply
Glyphosate Gross Profit to Decline, but Remain $750M Business in 2005
Gross profit ($ millions)
Global Biotech Crop Acreage Continues To Grow
Acres in millions
Monsanto's estimated biotech share of 2001 total crop acreage:
Monsanto's trait share 90+%
Monsanto's U.S. biotech acreage growth in 2002 estimated at 5%
Trait operating margins of 60-80%
Gross Profit Growth in Seeds and Traits to Continue Post-2002
$ millions
Growth to come from YieldGard rootworm corn, corn and stacked traits
Roundup Ready
Assumes no Brazilian planting approval of soybeans
Roundup Ready
Assumes no European import approvals of corn or rootworm corn
Roundup Ready
YieldGard
Roundup Ready Corn Has Significant Growth Potential
Value
Simpler, safer, more cost effective
90+% grower satisfaction
Farmers value lower costs, better yields at $17.50/acre
Roundup Ready Corn Growing Rapidly
Acres in Millions
1998 - 0.9 1999 - 2.3 2000 - 2.7 2001 - 4.5 2002F - 7.0
Roundup Ready Corn Treated with Roundup
[Picture]
Un-treated Weedy Check
[Picture]
YieldGard Rootworm Corn Expected to Launch in 2003
Value
Better control, lower costs, better yields, less insecticides
Current products cost $12-$14/acre; YieldGard to be priced competitively, but recognizing added value
Commercialization
Japan approved; expect U.S. in 2002
Launch up to approximately 1M acres in 2003; demand expected to outstrip supply
First to market, 2-3 yrs. ahead of the competition
YieldGard Rootworm vs. Insecticides
(Rootworm Injury Rating: Low Score Wins)
Economic Threshold - 3
YieldGard Rootworm - 1.8 Best Commercial Standard "Counter" - 2.4 Average of Next Top 4 Standard Insecticides - 3.0 Untreated Control - 4.1
[Picture of YieldGard Rootworm and Control]
YieldGard Rootworm Corn is not yet registered in the U.S.
Trait Stacking Provides Significant Opportunity
Corn Potential
Grower price per acre at U.S. retail
Monsanto Product Pipeline
          Gene/trait identification           High-throughput screening
Discovery
Duration           24-48+ months
Input Trait Candidates Farmer productivity           Grain yield           Environmental stress tolerance           Insect control           Roundup Ready
Output Trait Candidates Consumer benefit           Protein enhancements           Lipid enhancements           Carbohydrate enhancements           Bioactive compounds
          Proof of concept           Test gene in plants
Phase 1
Duration           12-24+ months
Input Trait Candidates Farmer productivity           Higher-yielding corn           YieldGard II insect-protected corn           Specialized corn
Output Trait Candidates Consumer benefit           Improved-oil soybeans for feed           Improved-energy corn III for feed           Healthier oil for food uses
         Early product development          Field trials and pre-regulatory studies
Phase 2
Duration           12-24+ months
Input Trait Candidates Farmer productivity           Enhanced Roundup Ready cotton           Higher-yielding soybeans           Roundup Ready and insect-protected soybeans
Output Trait Candidates Consumer benefit           Improved-protein soybeans for feed
         Advanced development          Efficacy and regulatory data
Phase 3
Duration           12-24+ months
Input Trait Candidates Farmer productivity           Roundup Ready / YieldGard rootworm-protected corn           Roundup Ready wheat           Hybrid Roundup Ready canola
Output Trait Candidates Consumer benefit           High starch/ethanol corn           Improved-energy corn II for feed
          Final regulatory submission           Produce seed and launch plan
Phase 4
Duration           12-36+ months
Input Trait Candidates Farmer productivity          YieldGard rootworm-protected corn          Bollgard II insect-protected cotton          Conservation tillage elite germplasm
Output Trait Candidates Consumer benefit          Processor Preferred soybeans          Improved-energy corn I for feed
Key Products in Late-Stage Approval Process
Cotton India
Bollgard
Request           Approval for planting
Current Status           Final regulatory approval granted
Next Key Event           Commercial planting began in 2002
Rootworm U.S.
YieldGard
Request           Approval for planting in U.S.; import in Japan
Current Status           Japan complete; U.S. food complete; USDA & EPA pending
Next Key Event           Approvals from EPA & USDA
Cotton U.S.
Bollgard II
Request           Approval for planting in U.S.; import in Japan
Current Status           Final phases of regulatory process in U.S. & Japan
Next Key Event           Approvals from EPA, USDA & Japan
Soybeans Brazil
Roundup Ready
Request           Approval for planting
Current Status           Pending court decision to unlock regulatory process
Next Key Event           Court ruling
Corn Europe
Roundup Ready
Request           Approval for import
Current Status           New regulations passed; restart of regulatory system pending
Next Key Event           Member states restart process
Peak Potential of Near-Term Products Pending Approvals is Large
$ millions
EBIT potential - $600 2001 Company EBIT - $809
EBIT potential of $600 million from:
Bollgard cotton in India
U.S. YieldGard rootworm corn
U.S. Bollgard II cotton
Roundup Ready soybeans in Brazil
U.S. Roundup Ready corn expansion with import approval in Europe
Associated incremental Roundup business
Future Gross Profit Builds on Roundup; Grows through Seeds and Traits
Gross profit ($ millions)
Cost Improvements to Continue to Benefit Earnings
Percent of sales
Longer-term objective:  SG&A 18% of sales
Earnings per Share and Free Cash per Share Improve as Business Recovers
$ per share
Earnings per Share
1999 - $1.33 2000 - $1.70 2001 - $1.80 2002F - $1.50 2003F - $1.90-$2.05
Free Cash per Share
1999 - ($1.14) 2000 - ($1.02) 2001 - $0.70 2002F - $1.50-$1.75 2003F - $1.65-$1.93
Note: 1999-2001 EPS includes $0.40 of goodwill amortization; all EPS numbers exclude special items. Specifically, 2002 EPS excludes 38 cents for Argentine bad-debt reserve and 16 cents for restructuring charges, and includes 8 cents related to sale of certain assets in Japan.
Receivables Management Remains a Focus
Receivables ($ millions)
2000 - 2,412 2001 - 2,307 2002F -2,200 2003F - 2,200
% Sales
2000 - 44% 2001 - 42% 2002F - 40% 2003F - 38%
Trend in receivables growth has shifted    Collections improved 9 percent in 2001    Receivables as percent of net sales declined 2 percentage points in 2001
Direct customer financing reduced through Bank One program
More restrictive credit policies instituted, particularly in Latin America
Restructured Latin American Business Reduces Risk
Net Trade Receivables at Year-End
$ millions
Argentina
2000 - 501 2001 - 582 2002F - 450
Brazil
2000 - 455 2001 - 473 2002F - 300
Latin America remains a critical long-term growth area    Crop acreage in Brazil and Argentina equals that of United States
Continue to take steps to reduce receivable risk and improve credit quality
Selling closer to planting season and reducing level of inventory in distribution channel
Sales expected to match market growth
Use of Free Cash Flow
Maintain current credit ratings with targeted debt/total capitalization of less than 25 percent at year-end; 30 percent at seasonal peak    Currently marketing long-term funding in early August; $750 million - $1 billion with multi-tranche maturities    Use free cash in 2002 to pay down debt to manage seasonal peaks
Potential for smaller investments in business to support integrated solutions
May consider share repurchase in 2003
Growth Drivers
Delivered
Effective management of Roundup post-patent
Integration and upgrade of the seed business
Strong grower adoption of biotech traits
'Best in class' R&D
Strong cost management
Positive free cash flow
Short Term
Deliver 'soft landing' for Roundup gross profit
Continue to build on strong seed performance
Grow current biotech traits in existing markets
Deliver pipeline products and gain additional biotech approvals
Improve Latin American operations
Deliver earnings and free cash flow growth
Medium Term
Accelerate seeds and traits growth globally
Maintain Roundup gross profit and brand loyalty
Realize full benefit of integrated solutions
Maintain robust R&D, and deliver pipeline products
Increase earnings and free cash flow
Efficiently return cash to shareholders


